A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection

Science

Volumn 348, Issue 6230, 2015, Pages 136-139

  Deng, Weiwen ^a   Gowen, Benjamin G ^a   Zhang, Li ^a   Wang, Lin ^a   Lau, Stephanie ^a   Iannello, Alexandre ^a   Xu, Jianfeng ^a   Rovis, Tihana L ^b   Xiong, Na ^c   Raulet, David H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF RIJEKA   (Croatia)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; CARRIER PROTEIN; HLA ANTIGEN CLASS 1; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; RECOMBINANT PROTEIN; UL16 BINDING PROTEIN 1, MOUSE;

CANCER; DISEASE TREATMENT; IMMUNE RESPONSE; LIGAND; RODENT; TUMOR;

ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DESENSITIZATION; DOWN REGULATION; ENDOCYTOSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR REJECTION; UPREGULATION; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MOUSE; NEOPLASMS; PROCEDURES; T LYMPHOCYTE;

MUS;

ANIMALS; CARRIER PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 84927658788     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1258867     Document Type: Article

References (28)

1. D. H. Raulet, Nat. Rev. Immunol. 3, 781-790 (2003).
2. D. H. Raulet, S. Gasser, B. G. Gowen, W. Deng, H. Jung, Annu. Rev. Immunol. 31, 413-441 (2013).
3. G. Chitadze, J. Bhat, M. Lettau, O. Janssen, D. Kabelitz, Scand. J. Immunol. 78, 120-129 (2013).
4. V. Groh, J. Wu, C. Yee, T. Spies, Nature 419, 734-738 (2002).
5. H. Song, J. Kim, D. Cosman, I. Choi, Cell. Immunol. 239, 22-30 (2006).
6. H. R. Salih, D. Goehlsdorf, A. Steinle, Hum. Immunol. 67, 188-195 (2006).
7. I. Waldhauer, A. Steinle, Cancer Res. 66, 2520-2526 (2006).
8. K. Wiemann et al., J. Immunol. 175, 720-729 (2005).
9. M. von Lilienfeld-Toal et al., Cancer Immunol. Immunother. 59, 829-839 (2010).
10. N. Guerra et al., Immunity 28, 571-580 (2008).
11. R. A. Eagle et al., PLOS ONE 4, e4503 (2009).
12. M. Xia et al., Circulation 124, 2933-2943 (2011).
13. L. N. Carayannopoulos, O. V. Naidenko, D. H. Fremont, W. M. Yokoyama, J. Immunol. 169, 4079-4083 (2002).
14. T. J. Nice, L. Coscoy, D. H. Raulet, J. Exp. Med. 206, 287-298 (2009).
15. R. Glas et al., J. Exp. Med. 191, 129-138 (2000).
16. A. Diefenbach, E. R. Jensen, A. M. Jamieson, D. H. Raulet, Nature 413, 165-171 (2001).
17. D. E. Oppenheim et al., Nat. Immunol. 6, 928-937 (2005).
18. C. A. Crane et al., Proc. Natl. Acad. Sci. U.S.A. 111, 12823-12828 (2014).
19. N. Nausch, I. E. Galani, E. Schlecker, A. Cerwenka, Blood 112, 4080-4089 (2008).
20. J. D. Coudert, L. Scarpellino, F. Gros, E. Vivier, W. Held, Blood 111, 3571-3578 (2008).
21. B. Zafirova et al., Immunity 31, 270-282 (2009).
22. S. Sheppard et al., Blood 121, 5025-5033 (2013).
23. M. Ardolino et al., J. Clin. Invest. 124, 4781-4794 (2014).
24. A. Märten, M. von Lilienfeld-Toal, M. W. Büchler, J. Schmidt, Int. J. Cancer 119, 2359-2365 (2006).
25. A. Clayton et al., J. Immunol. 180, 7249-7258 (2008).
26. O. Ashiru et al., Cancer Res. 70, 481-489 (2010).
27. R. B. Taylor, W. P. Duffus, M. C. Raff, S. de Petris, Nat. New Biol. 233, 225-229 (1971).
28. E. Narni-Mancinelli et al., Science 335, 344-348 (2012).